B. Cepacia Hits ICUs Again, Raises Manufacturing Controls Questions
Another outbreak of B. cepacia at hospital intensive care units in multiple states implicates manufacturing and supply chain controls on aqueous non-sterile drug products, particularly for those marketed over the counter under OTC monographs.
You may also be interested in...
More testing expected after B. cepacia contamination of OTC liquid drug products, including for Rx drug products.
Agency will provide guidance in wake of recent outbreaks of Burkholderia cepacia in non-sterile, water-based drug products.
Some ingredient risks to consider: IV castor oil hypersensitivity; oral liquid bioburden; elm in the coconut.